vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Elme Communities (ELME). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($70.9M vs $62.1M, roughly 1.1× Elme Communities). Adaptive Biotechnologies Corp runs the higher net margin — 4.7% vs -198.9%, a 203.6% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs 1.7%). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (28.1% CAGR vs 2.7%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.
ADPT vs ELME — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.9M | $62.1M |
| Net Profit | $3.4M | $-123.5M |
| Gross Margin | 73.6% | 61.1% |
| Operating Margin | -27.1% | -183.3% |
| Net Margin | 4.7% | -198.9% |
| Revenue YoY | 35.1% | 1.7% |
| Net Profit YoY | — | -4058.7% |
| EPS (diluted) | — | $-1.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $70.9M | — | ||
| Q4 25 | $71.7M | — | ||
| Q3 25 | $94.0M | $62.1M | ||
| Q2 25 | $58.9M | $62.1M | ||
| Q1 25 | $52.4M | $61.5M | ||
| Q4 24 | $47.5M | $61.3M | ||
| Q3 24 | $46.4M | $61.1M | ||
| Q2 24 | $43.2M | $60.1M |
| Q1 26 | $3.4M | — | ||
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | $-123.5M | ||
| Q2 25 | $-25.6M | $-3.6M | ||
| Q1 25 | $-29.9M | $-4.7M | ||
| Q4 24 | $-33.7M | $-3.0M | ||
| Q3 24 | $-32.1M | $-3.0M | ||
| Q2 24 | $-46.2M | $-3.5M |
| Q1 26 | 73.6% | — | ||
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | 61.1% | ||
| Q2 25 | 69.4% | 63.5% | ||
| Q1 25 | 67.6% | 64.2% | ||
| Q4 24 | 62.0% | 62.9% | ||
| Q3 24 | 64.1% | 63.5% | ||
| Q2 24 | 55.3% | 63.4% |
| Q1 26 | -27.1% | — | ||
| Q4 25 | -17.8% | — | ||
| Q3 25 | 10.9% | -183.3% | ||
| Q2 25 | -42.5% | 9.6% | ||
| Q1 25 | -56.4% | 7.8% | ||
| Q4 24 | -71.3% | 10.4% | ||
| Q3 24 | -70.3% | 11.0% | ||
| Q2 24 | -109.6% | 9.8% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | -198.9% | ||
| Q2 25 | -43.5% | -5.7% | ||
| Q1 25 | -56.9% | -7.6% | ||
| Q4 24 | -71.0% | -4.9% | ||
| Q3 24 | -69.1% | -4.9% | ||
| Q2 24 | -107.0% | -5.8% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | $-1.40 | ||
| Q2 25 | $-0.17 | $-0.04 | ||
| Q1 25 | $-0.20 | $-0.05 | ||
| Q4 24 | $-0.22 | $-0.04 | ||
| Q3 24 | $-0.22 | $-0.03 | ||
| Q2 24 | $-0.31 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.6M | $7.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $908.9M |
| Total Assets | $505.9M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.6M | — | ||
| Q4 25 | $70.5M | — | ||
| Q3 25 | $55.0M | $7.1M | ||
| Q2 25 | $43.2M | $4.8M | ||
| Q1 25 | $50.6M | $6.4M | ||
| Q4 24 | $47.9M | $6.1M | ||
| Q3 24 | $38.1M | $4.8M | ||
| Q2 24 | $59.8M | $5.6M |
| Q1 26 | — | — | ||
| Q4 25 | $218.8M | — | ||
| Q3 25 | $204.4M | $908.9M | ||
| Q2 25 | $179.7M | $1.0B | ||
| Q1 25 | $190.4M | $1.1B | ||
| Q4 24 | $202.7M | $1.1B | ||
| Q3 24 | $223.8M | $1.1B | ||
| Q2 24 | $241.6M | $1.1B |
| Q1 26 | $505.9M | — | ||
| Q4 25 | $512.7M | — | ||
| Q3 25 | $490.6M | $1.7B | ||
| Q2 25 | $496.6M | $1.8B | ||
| Q1 25 | $510.9M | $1.8B | ||
| Q4 24 | $539.4M | $1.8B | ||
| Q3 24 | $558.5M | $1.9B | ||
| Q2 24 | $584.9M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.9M |
| Free Cash FlowOCF − Capex | — | $7.2M |
| FCF MarginFCF / Revenue | — | 11.6% |
| Capex IntensityCapex / Revenue | — | 14.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $86.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.1M | — | ||
| Q3 25 | $-7.1M | $15.9M | ||
| Q2 25 | $-12.4M | $29.8M | ||
| Q1 25 | $-28.5M | $16.2M | ||
| Q4 24 | $-12.5M | $95.2M | ||
| Q3 24 | $-27.1M | $20.7M | ||
| Q2 24 | $-17.3M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | $7.2M | ||
| Q2 25 | $-13.1M | $21.1M | ||
| Q1 25 | $-29.7M | $10.5M | ||
| Q4 24 | $-12.6M | $47.9M | ||
| Q3 24 | $-27.4M | $8.8M | ||
| Q2 24 | $-19.0M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | 11.6% | ||
| Q2 25 | -22.2% | 34.1% | ||
| Q1 25 | -56.7% | 17.1% | ||
| Q4 24 | -26.5% | 78.1% | ||
| Q3 24 | -59.0% | 14.4% | ||
| Q2 24 | -44.1% | 34.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.4% | 14.0% | ||
| Q2 25 | 1.1% | 14.0% | ||
| Q1 25 | 2.4% | 9.2% | ||
| Q4 24 | 0.2% | 77.4% | ||
| Q3 24 | 0.7% | 19.4% | ||
| Q2 24 | 4.0% | 13.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
Segment breakdown not available.
ELME
| Residential Segment | $57.7M | 93% |
| Other | $4.4M | 7% |
